In a prospective open study 44 Israeli patients with rheumatoid arthritis were treated with weekly low dose methotrexate (MTX) for up to 36 months. Nine patients withdrew from the study: six because of side effects and three due to inefficacy. One patient died of septicaemia following septic arthritis. Significant improvement, graded by Ritchie articular index, grip strength, physician's global assessment, erythrocyte sedimentation rate (ESR), and platelet counts, was noticed in response to treatment. Seronegative patients had a better clinical response. Transient gastrointestinal symptoms were common and correlated with increases of serum aspartate transaminase (AST). HLA-DR1 and DR7 were significantly associated with increased serum AST concentrations.
The use of methotrexate (MTX), a folic acid antagonist, as an effective agent suppressing synovitis in rheumatoid arthritis (RA) was first reported by Gubner et al in 1951. 1 The drug was not in use for many years in patients with RA, however, although there has been extensive experience with MTX in the treatment of psoriasis. 3 Clinical studies in recent years established its efficacy in the treatment of patients with RA not responding to other drugs.49 Although rapid therapeutic benefit was observed in all short term studies,'-7 the longer term effectiveness of MTX has been shown only in a few detailed reports.8 9 We conducted an open prospective study to (a) assess the short and medium term efficacy of MTX in our patients with RA, (b) study the various side effects and their interrelationships, and (c) search for a genetic predisposition to the therapeutic response or side effects of MTX 114 (2) 115 (1) 119 (2) 111 (2) 112 (51) 117 (5) 113 (3) Platclets(x 109/I)
399 (22) 352 (16) 352 (18) 354 (24) 355 (30) testinal and central nervous system symptoms was less significant (p=0.055).
PREDNISONE DOSAGE
Twenty five patients (57%) required prednisone treatment before the start of the study, with a mean dose of 10.3 mg/day (range 5-25). In the course of the study 10 patients were completely withdrawn from steroids and the mean prednisone dosage in the others decreased to 6-5 mg/day (p<005).
ASSOCIATION OF HLA ANTIGENS AND THE CLINICAL AND LABORATORY FINDINGS
The prevalence of HLA-A, B, C, and DR antigens of our patients with RA showed no significant difference from that of the normal Israeli control population (data not shown). Nor was there any association of the antigens with clinical or laboratory parameters indicating drug efficacy. An increase of serum AST concentrations, however, after MTX treatment was observed in HLA-DR7 or DR1 positive patients (p<002 and p<0-05 respectively) ( Liver fibrosis was reported in psoriatic patients receiving prolonged MTX treatment but not in patients with RA.8 9 15 Furthermore, no correlation was found between an increase of transaminase concentrations and hepatic changes in serial liver biopsy specimens.8 As in previous studies-9 14 we also found frequent increases in transaminase concentrations, which decreased after dosage reduction. Interestingly, in ouI patients gastrointestinal symptoms had a strong correlation with serum AST increases (p=0-0006) and usually appeared early in the course of treatment, predicting liver function abnormalities. The association between raised serum AST and HLA-DR7 and DR1 is also unique and has not been reported previously.5 8 14 In conclusion, the results of this study suggest that methotrexate is an effective drug in the treatment of severe rheumatoid arthritis over a period of six to 36 months. Yet, the exact place of methotrexate among second line drugs has to be determined. 
